NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 65,000 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 65,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the completion of the transaction, the chief accounting officer owned 24,353 shares in the company, valued at approximately $869,158.57. This trade represents a 72.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS traded up $0.45 during mid-day trading on Wednesday, hitting $36.56. The company’s stock had a trading volume of 938,780 shares, compared to its average volume of 972,753. NewAmsterdam Pharma Company N.V. has a 1 year low of $16.78 and a 1 year high of $42.21. The stock has a market cap of $4.27 billion, a price-to-earnings ratio of -20.42 and a beta of 0.02. The business’s fifty day moving average is $33.02 and its two-hundred day moving average is $34.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The business had revenue of $3.04 million during the quarter. Analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in NAMS. Capital World Investors lifted its position in shares of NewAmsterdam Pharma by 17.1% during the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after buying an additional 1,434,986 shares in the last quarter. Duquesne Family Office LLC lifted its position in shares of NewAmsterdam Pharma by 131.2% during the 3rd quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after buying an additional 1,091,525 shares in the last quarter. Castle Hook Partners LP purchased a new position in shares of NewAmsterdam Pharma during the 4th quarter valued at approximately $38,062,000. Adage Capital Partners GP L.L.C. lifted its position in shares of NewAmsterdam Pharma by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after buying an additional 1,062,359 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of NewAmsterdam Pharma by 96.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,725,662 shares of the company’s stock valued at $60,536,000 after buying an additional 845,110 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on NAMS shares. Guggenheim upped their price objective on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. Needham & Company LLC upped their price objective on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Truist Financial started coverage on NewAmsterdam Pharma in a research report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, NewAmsterdam Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.00.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.